|Bid||0.1100 x 194091900|
|Ask||0.1150 x 380640100|
|Day's range||0.1050 - 0.1150|
|52-week range||0.0400 - 0.1800|
|Beta (5Y monthly)||2.45|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.15|
Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer's Disease (AD) biomarker study, which validates the Company's planned Xanamem program in AD.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
It hasn't been the best quarter for Actinogen Medical Limited ( ASX:ACW ) shareholders, since the share price has...